CCM® therapy is covered by Medicare

Medicare and Medicare Advantage cover CCM® therapy for FDA-indicated patients aged 18 or older who have not undergone a heart transplant.
Click here for more information
  • Home
  • Patients
    • Causes
    • Symptoms
    • Diagnosis
    • Treatment
    • Patient Stories
  • Providers
    • Indications & Patient Selection
    • Procedure and Mode of Action
    • Heart Failure Resources
    • Reimbursement
    • Instructions for Use and Product Manuals
  • Our Science
    • Clinical Studies
      • Aim Higher Study
      • Integra-D
    • Publications
  • Company
    • Executive Team
    • News Center
    • Safety Information
    • Ethics & Compliance
    • Grants & Donations
    • Careers
    • Contact Us
  • Find A Provider
  • REGION
    • North America
      • United States
      • Pacific
      • Australia
      • New Zeland
    • Pacific
      • Australia
      • New Zeland
    • Europe
      • Austria
      • Belgium
      • Czech Republic
      • Denmark
      • Finland
      • France
    • Europe
      • Germany
      • Hungary
      • Ireland
      • Italy
      • Netherlands
      • Norway
    • Europe
      • Poland
      • Portugal
      • Spain
      • Sweden
  • Home
  • Patients
    • Causes
    • Symptoms
    • Diagnosis
    • Treatment
    • Patient Stories
  • Providers
    • Indications & Patient Selection
    • Procedure and Mode of Action
    • Heart Failure Resources
    • Reimbursement
    • Instructions for Use and Product Manuals
  • Our Science
    • Clinical Studies
      • Aim Higher Study
      • Integra-D
    • Publications
  • Company
    • Executive Team
    • News Center
    • Safety Information
    • Ethics & Compliance
    • Grants & Donations
    • Careers
    • Contact Us
  • Find A Provider
  • REGION
    • North America
      • United States
      • Pacific
      • Australia
      • New Zeland
    • Pacific
      • Australia
      • New Zeland
    • Europe
      • Austria
      • Belgium
      • Czech Republic
      • Denmark
      • Finland
      • France
    • Europe
      • Germany
      • Hungary
      • Ireland
      • Italy
      • Netherlands
      • Norway
    • Europe
      • Poland
      • Portugal
      • Spain
      • Sweden

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

by Impulse Dynamics | Dec 18, 2017 | Press Releases

NEWS The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system...

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.

by Impulse Dynamics | Aug 7, 2017 | Press Releases

NEWS Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study. Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a...

Impulse Dynamics Completes $45 million Financing Round

by Impulse Dynamics | May 11, 2017 | Press Releases

NEWS Impulse Dynamics Completes $45 million Financing Round Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has...

Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe

by Impulse Dynamics | Mar 3, 2017 | Press Releases

NEWS Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is...

Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award

by Impulse Dynamics | Sep 12, 2016 | Press Releases

NEWS Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award September 12, 2016 – Impulse Dynamics, developer of the Optimizer™ IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the...
« Older Entries
Next Entries »

Recent Posts

  • Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy
  • Impulse Dynamics Announces First International Implants of the Optimizer Smart Mini System in Italy
  • Late-breaking Results Show Efficacy for CCM in Patients With HFpEF
  • IMPULSE DYNAMICS COMPLETES $101M FINANCING ROUND
  • IMPULSE DYNAMICS ANNOUNCES FIRST IMPLANTS OF OPTIMIZER SMART MINI

Recent Comments

    Archives

    • November 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • November 2021
    • October 2021
    • July 2021
    • February 2021
    • January 2021
    • April 2020
    • March 2020
    • December 2019
    • November 2019
    • October 2019
    • July 2019
    • March 2019
    • May 2018
    • December 2017
    • August 2017
    • May 2017
    • March 2017
    • September 2016
    • May 2016
    • March 2016
    • January 2016
    • November 2015
    • August 2015
    • July 2015
    • January 2015
    • December 2014

    Categories

    • News and Events
    • Press Releases

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org